Nektar Therap (NKTR.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec16

HC Wainwright Raises Nektar Therapeutics Price Target to $135

18:16

Nektar Therapeutics' Drug Rezpegaldesleukin Fails to Meet Main Goal in Mid-Stage Study, Shares Fall

13:59

Nektar Therapeutics Announces Positive Phase 2b Results for Rezpegaldesleukin in Severe Alopecia Areata

12:31

Nov28

Citi initiates coverage of Nektar Therapeutics with a Buy rating and sets a $102 price target

13:02

Nov17

William Blair Maintains Hold Rating on NKTR

23:26

Nov11

H.C. Wainwright Reiterates Buy Rating on Nektar Therapeutics

12:02

Schedules & Filings

Schedules

Filings

Nov6

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 11.79 M, Net Income -35.52 M, EPS -1.8748

Aug7

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 11.18 M, Net Income -41.59 M, EPS -2.9525

Jun9

Reverse Stock Split(EST)

1-for-15 Reverse Stock Split

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change